KerusCloud®

Don’t roll the dice on your clinical trial.

KerusCloud® allowed us to develop our study design to recognize the transformative potential of EXN407 whilst ensuring we account for and minimize any potential risks.
Loic Lhuillier
Chief Operating Officer

Clinical Trial Simulation Software to De-risk Study Design

KerusCloud® is an advanced clinical trial simulation software that helps research teams de-risk studies by design. This cloud-based platform enables you to model and analyze thousands of virtual trial scenarios—optimizing endpoints, recruitment strategies, and estimand frameworks before a real study begins. With KerusCloud®, you get data-backed insights that accelerate development, reduce costs, and increase the probability of trial success.

Optimize patient recruitment

  • Visualize patient recruitment scenarios: Simulate recruitment rates and site numbers to understand how population choice impacts your study’s length and probability of success.
  • Forecast study timelines more accurately: Analyze your recruitment strategies in silico to better understand the operational landscape and impact of potential adjustments to recruitment strategies, sample sizes, and decision criteria, ensuring your real trial stays on track.

Explore patient recruitment capabilities

Optimize study designs with advanced simulations 

  • Stay ahead of regulatory requirements: Ensure study designs comply with ICH E9(R1) guidelines. Incorporate estimand strategies that align with FDA and EMA requirements, keeping your study compliant while delivering results ready for regulatory approval.
  • Identify the most effective study design: Explore a range of fixed and adaptive study designs in silico to evaluate how they impact study outcomes and enable you to reduce costs, accelerate timelines, and minimize patient burden.
  • Enhance trial flexibility and manage uncertainty: Use KerusCloud’s probabilistic framework to estimate the likelihood of different outcomes as new data emerges, and refine your development plan accordingly.

Explore design & analysis options

Mimic real-world conditions with synthetic data

  • Leverage virtual population data: Manage complex virtual datasets and simulate your study in a way that accurately mimics actual clinical trial dynamics.
  • Access predefined data libraries: Rapidly set up simulations that include virtual patient populations, recruitment scenarios and various adaptive design options.
  • Streamline trial execution: Save time and resources by creating external control arms, reducing the need for extensive recruitment in clinical trials.
  • Maintain patient privacy: Enable the sharing of regulated or sensitive data while maintaining privacy and compliance through anonymization.
  • Address imbalanced or missing data: Generate large, auto-labelled datasets to support predictive modelling, machine learning, and AI so you can address imbalanced data in clinical studies.

Explore dataset generation

Visualize, export, and explore results

  • Choose the right study design the first time: Use the interactive heatmap to visualize how different decisions affect the study’s probability of success.
  • Support transparent decision-making: Share synthetic data, recruitment profiles, simulation results, and reports with your team throughout your trial.
  • Analyze patient populations, recruitment, and trial dynamics: Integrate with R and other analytics tools to create tailored visualizations.

 

Suggested For You

perspectives

April 27th, 2026

From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

webinar

March 26th, 2026

Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

webinar

April 30th, 2026

Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions